In our study, 86% (25/29) of the DNAs from resected tissues, in which tumour remnants were expected (i.e. tumours of the UFS group and tumours of the ypT1 NAT sub-group), showed detectable KRAS mutations. The gene discussed is BRD2; the disease is neoplasm.